GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Action(s) initiated or orders passed
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts less than Nifty Midcap 150 and 0.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
GlaxoSmithKline Pharmaceuticals has received an Appellate Order dated 17 June 2025 from the Joint Commissioner (Appeals) of CGST in Indore, Madhya Pradesh. The order raises a total demand of Rs. 3,06,68,432, which includes a tax component of Rs. 1.37 crore and a penalty of Rs. 1.69 crore (interest not quantified). The demand relates to alleged input tax credit mismatches between the company's GST returns and what its suppliers reported in their GST returns. The company has stated there is no impact on its financial operations and is evaluating the order to take appropriate action.
The demand of around Rs. 3.07 crore is small relative to GSK Pharma's overall size and is not expected to affect operations. However, shareholders should note the company may need to contest this and a further penalty or interest charge could add to the liability.